The future of multiple sclerosis: Progression focused therapies and RWE
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS)...
Topic
Marketplace
Mitigating data disruptions in open claims datasets
Healthcare data now accounts for approximately 30% of global data volume and with this surge in...
An integrated approach for deeper insight with both open and closed claims data
Pharma teams are under sharper financial scrutiny and policy pressure than they've been in years,...
Menopause at a turning point: RWD matters more than ever
A recent CNBC article used HealthVerity real-world data (RWD) to highlight a shortage of estrogen...
Subtler scopes: Where IRA drug negotiations meet Part D redesigns
Understanding how the IRA’s multiple provisions interact to induce cost-related change The...
TrOOPs: Tracking cost implications under IRA Part D reforms
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic...
Open claims vs. closed payer claims: What’s the difference?
Open claims and closed payer claims data are essential for understanding the status and activities...
Why RWE programs fail under regulatory scrutiny — and what leaders can do about it
FDA has made its expectations for RWE clearer and more structured through recent guidance and...
HPV vaccination trends from 2016 to 2025: Progress and missed opportunities
by: Alexandra Miller, MPH Human papillomavirus (HPV) is one of the most common sexually...
Primary biliary cholangitis: Disease burden, treatments and RWD gaps
Understanding PBC and today’s treatment landscape Primary biliary cholangitis (PBC) is a chronic...